Scholarlink

<p>The efficacy of the combination of hyperbaric oxygen therapy and the radionuclide treatment in targeting and treating metastatic bone pain due to tumors was analyzed in this study. Thirty-nine patients with metastatic bone tumors were divided into 2 groups. Group A consisted of patients receiving hyperbaric oxygen therapy combined with radionuclide therapy, and group B had patients receiving radionuclide therapy alone. Pain scores, sleep scores before and after treatment and the proportion of patients whose analgesic dosage was reduced within 24 h in both groups were analyzed at different time points before and after drug administration, and the scores between the groups were compared. All patients received 1 session of radionuclide therapy, with patients in group A receiving in combination with 1 course of hyperbaric oxygen therapy. On the seventh day after treatment, patients in Group A exhibited significantly lower pain scores than those in Group B, particularly during the initial 48 h. On day 30 post-treatment, sleep scores decreased in both patient groups. After 7 days of treatment, the proportion of patients in Group A and Group B experiencing painkiller reduction at different time points 24 h was 72.2% and 42.9%, respectively. There were no significant differences in bone marrow suppression status and renal function measurements between the two groups of patients before and after treatment. Hyperbaric oxygen combined with radionuclide therapy is safe and provides faster relief of bone pain in patients with bone metastases. Hyperbaric oxygen therapy can enhance the therapeutic effect of radionuclide therapy, and this combination warrants further evaluation for potential use in a clinical setting.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Safety and efficacy of the combination of hyperbaric oxygen and 177Lu-DOTA-IBA in treating metastatic bone pain due to tumors

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月21日

查看全文
  • Yingwei Wang,
  • Ya Liu,
  • Jian Yang,
  • Dengsai Peng,
  • Qingchu Hua,
  • Chunfang Zhang,
  • Ying Zhang,
  • Wei Wang,
  • Yue Chen

摘要

The efficacy of the combination of hyperbaric oxygen therapy and the radionuclide treatment in targeting and treating metastatic bone pain due to tumors was analyzed in this study. Thirty-nine patients with metastatic bone tumors were divided into 2 groups. Group A consisted of patients receiving hyperbaric oxygen therapy combined with radionuclide therapy, and group B had patients receiving radionuclide therapy alone. Pain scores, sleep scores before and after treatment and the proportion of patients whose analgesic dosage was reduced within 24 h in both groups were analyzed at different time points before and after drug administration, and the scores between the groups were compared. All patients received 1 session of radionuclide therapy, with patients in group A receiving in combination with 1 course of hyperbaric oxygen therapy. On the seventh day after treatment, patients in Group A exhibited significantly lower pain scores than those in Group B, particularly during the initial 48 h. On day 30 post-treatment, sleep scores decreased in both patient groups. After 7 days of treatment, the proportion of patients in Group A and Group B experiencing painkiller reduction at different time points 24 h was 72.2% and 42.9%, respectively. There were no significant differences in bone marrow suppression status and renal function measurements between the two groups of patients before and after treatment. Hyperbaric oxygen combined with radionuclide therapy is safe and provides faster relief of bone pain in patients with bone metastases. Hyperbaric oxygen therapy can enhance the therapeutic effect of radionuclide therapy, and this combination warrants further evaluation for potential use in a clinical setting.